Emergence of central nervous system myeloma in the era of novel agents

Hematological Oncology

Volumn 30, Issue 4, 2012, Pages 170-174

  Gangatharan, Shane A ^a   Carney, Dennis A ^a   Prince, H Miles ^a,b   Wolf, Max M ^a,b   Januszewicz, E Henry ^a   Ritchie, David S ^a,b   Harrison, Simon J ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Bortezomib; CNS; Lenalidomide; Myeloma; Thalidomide

Indexed keywords

BORTEZOMIB; CD38 ANTIGEN; CD56 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; HYDROCORTISONE; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; LENALIDOMIDE; METHOTREXATE; PARAPROTEIN; PREDNISOLONE; ROMIDEPSIN; SYNDECAN 1; THALIDOMIDE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER TRANSPLANTATION; CENTRAL NERVOUS SYSTEM MYELOMA; CLINICAL ARTICLE; DISEASE SEVERITY; HUMAN; MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CENTRAL NERVOUS SYSTEM NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; PYRAZINES; STEM CELL TRANSPLANTATION; SURVIVAL RATE; THALIDOMIDE; TRANSPLANTATION, AUTOLOGOUS;

EID: 84870953387     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.1021     Document Type: Article

References (15)

1. Petersen SL, Wagner A, Gimsing P. Cerebral and meningeal multiple myeloma after autologous stem cell transplantation. A case report and review of the literature. Am J Hematol 1999; 62(4): 228-233.
2. Fassas AB, Muwalla F, Berryman T, et al. Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations. Br J Haematol 2002; 117(1): 103-108.
3. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008; 111(5): 2521-2526.
4. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111(5): 2516-2520.
5. Stewart AK, Richardson PG, San-Miguel JF. How I treat multiple myeloma in younger patients. Blood 2009; 114(27): 5436-5443.
6. Fassas AB, Ward S, Muwalla F, et al. Myeloma of the central nervous system: strong association with unfavorable chromosomal abnormalities and other high-risk disease features. Leuk Lymphoma 2004; 45(2): 291-300.
7. Nieuwenhuizen L, Biesma DH. Central nervous system myelomatosis: review of the literature. Eur J Haematol 2008; 80(1): 1-9.
8. Chamberlain MC, Glantz M. Myelomatous meningitis. Cancer 2008; 112(7): 1562-1567.
9. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348(19): 1875-1883.
10. Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol 2010; 21(2): 325-330.
11. Yutaka H, Mariko Y, Shinichiro O, Kunihiko M, Yusuke T, Yasuo I. Thalidomide for the treatment of leptomeningeal multiple myeloma. Eur J Haematol 2006; 76(4): 358-359.
12. Hemeryck A, Geerts R, Monbaliu J, et al. Tissue distribution and depletion kinetics of bortezomib and bortezomib-related radioactivity in male rats after single and repeated intravenous injection of 14 C-bortezomib. Cancer Chemother Pharmacol 2007; 60(6): 777-787.
13. Shain KH, Dalton WS. Environmental-mediated drug resistance: a target for multiple myeloma therapy. Expert Rev Hematol 2009; 2(6): 649-662.
14. Reske T, Fulciniti M, Munshi NC. Mechanism of action of immunomodulatory agents in multiple myeloma. Med Oncol 2010; 27(Suppl 1): S7-S13.
15. Jia D, Koonce NA, Halakatti R, et al. Repression of multiple myeloma growth and preservation of bone with combined radiotherapy and anti-angiogenic agent. Radiat Res 2010; 173(6): 809-817.